These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 36358716)

  • 21. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 22. Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers.
    Li M; Spakowicz D; Burkart J; Patel S; Husain M; He K; Bertino EM; Shields PG; Carbone DP; Verschraegen CF; Presley CJ; Otterson GA; Kendra K; Owen DH
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2541-2546. PubMed ID: 31367835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis.
    Wang Z; Zhan P; Lv Y; Shen K; Wei Y; Liu H; Song Y
    Transl Lung Cancer Res; 2019 Jun; 8(3):214-226. PubMed ID: 31367535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.
    Liu C; Guo H; Mao H; Tong J; Yang M; Yan X
    Front Oncol; 2022; 12():753234. PubMed ID: 35280736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of proton pump inhibitor use with survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Chen B; Yang C; Dragomir MP; Chi D; Chen W; Horst D; Calin GA; Li Q
    Ther Adv Med Oncol; 2022; 14():17588359221111703. PubMed ID: 35860836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis.
    Tan Q; Liu S; Liang C; Han X; Shi Y
    Thorac Cancer; 2018 Oct; 9(10):1220-1230. PubMed ID: 30151899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis.
    Zou Y; Zou X; Zheng S; Tang H; Zhang L; Liu P; Xie X
    Ther Adv Med Oncol; 2020; 12():1758835920940928. PubMed ID: 32874208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: A systematic review and meta-analysis.
    Su L; Zhang M; Zhang W; Cai C; Hong J
    Medicine (Baltimore); 2017 Mar; 96(11):e6364. PubMed ID: 28296774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis.
    Wu Y; Xu J; Du C; Wu Y; Xia D; Lv W; Hu J
    Front Oncol; 2019; 9():1161. PubMed ID: 31750249
    [No Abstract]   [Full Text] [Related]  

  • 31. Impact of Age on the Efficacy of Immune Checkpoint Inhibitor-Based Combination Therapy for Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Yan X; Tian X; Wu Z; Han W
    Front Oncol; 2020; 10():1671. PubMed ID: 33072551
    [No Abstract]   [Full Text] [Related]  

  • 32. A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies.
    Cao D; Xu H; Xu X; Guo T; Ge W
    Oncoimmunology; 2018; 7(11):e1507262. PubMed ID: 30377569
    [No Abstract]   [Full Text] [Related]  

  • 33. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
    Tian T; Yu M; Yu Y; Wang K; Tian P; Luo Z; Ding Z; Wang Y; Gong Y; Zhu J; Zou B; Sio TT; Alves A; Liu Y; Huang M; Lu Y
    Transl Lung Cancer Res; 2022 Jun; 11(6):1027-1037. PubMed ID: 35832458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
    Xie E; Yeo YH; Scheiner B; Zhang Y; Hiraoka A; Tantai X; Fessas P; de Castro T; D'Alessio A; Fulgenzi CAM; Xu S; Tsai HM; Kambhampati S; Wang W; Keenan BP; Gao X; Xing Z; Pinter M; Lin YJ; Guo Z; Vogel A; Tanaka T; Kuo HY; Kelley RK; Kudo M; Yang JD; Pinato DJ; Ji F
    JAMA Oncol; 2023 Oct; 9(10):1423-1431. PubMed ID: 37615958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.
    Cassidy MR; Wolchok RE; Zheng J; Panageas KS; Wolchok JD; Coit D; Postow MA; Ariyan C
    EBioMedicine; 2017 Apr; 18():56-61. PubMed ID: 28356222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Outcome of Immune Checkpoint Inhibitors.
    Xie X; Liu J; Yang H; Chen H; Zhou S; Lin H; Liao Z; Ding Y; Ling L; Wang X
    Cancer Invest; 2019; 37(6):265-274. PubMed ID: 31304800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Prognostic Significance of Baseline Neutrophil-to-Lymphocyte Ratio in Melanoma Patients Receiving Immunotherapy.
    Li Y; Meng Y; Sun H; Ye L; Zeng F; Chen X; Deng G
    J Immunother; 2022 Jan; 45(1):43-50. PubMed ID: 34510106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer.
    Zheng L; Xiong A; Wang S; Xu J; Shen Y; Zhong R; Lu J; Chu T; Zhang W; Li Y; Zheng X; Han B; Zhong H; Nie W; Zhang X
    Front Immunol; 2023; 14():1094378. PubMed ID: 36776882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Antacid Use on Immune Checkpoint Inhibitors in Advanced Solid Cancer Patients: A Systematic Review and Meta-analysis.
    Deng R; Zhang H; Li Y; Shi Y
    J Immunother; 2023 Feb-Mar 01; 46(2):43-55. PubMed ID: 36301729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.